You will be provided with a reference and some statements. Please determine whether each statement is 'supported', 'unsupported', or 'unknown' with respect to the reference. Please note:
First, assess whether the reference contains any valid content. If the reference contains no valid information, such as a 'page not found' message, then all statements should be considered 'unknown'.
If the reference is valid, for a given statement: if the facts or data it contains can be found entirely or partially within the reference, it is considered 'supported' (data accepts rounding); if all facts and data in the statement cannot be found in the reference, it is considered 'unsupported'.

You should return the result in a JSON list format, where each item in the list contains the statement's index and the judgment result, for example:
[
    {
        "idx": 1,
        "result": "supported"
    },
    {
        "idx": 2,
        "result": "unsupported"
    }
]

Below are the reference and statements:
<reference>
The Effect of Increasing Dialysate Magnesium on... : Clinical Journal of the American Society of Nephrology



Advertisement
ASN Publications
ASN Publications
Search
Search
Search
History
Log in
Navbar

Menu

Articles
Subject Collections
Authors and Reviewers
Trainees
Podcasts
Journal Info
More
More menu items
Search
History
Button group.
Check Access
Permissions
Share
Cite
Favorite
Original Articles
:
Maintenance Dialysis
The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease
A Randomized, Controlled Clinical Trial
Iain

Bressendorff
2
Ditte

Hansen
2
Morten

Schou
3
Andreas

Pasch
5
Lisbet

Brandi
1
Authors and Affiliations
Clinical Journal of the American Society of Nephrology

13
(
9
)
:p
1373
-
1380
,
September 2018
.
|
DOI:
10.2215/CJN.13921217
Infographic
SDC
Abstract
Background and objectives
Serum calcification propensity is a novel functional test that quantifies the functionality of the humeral system of calcification control. Serum calcification propensity is measured by T
50
, the time taken to convert from primary to secondary calciprotein particle in the serum. Lower T
50
represents higher calcification propensity and is associated with higher risk of cardiovascular events and death in patients with ESKD. Increasing magnesium in serum increases T
50
, but so far, no clinical trials have investigated whether increasing serum magnesium increases serum calcification propensity in subjects with ESKD.
Design, setting, participants, & measurements
We conducted a single-center, randomized, double-blinded, parallel group, controlled clinical trial, in which we examined the effect of increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days compared with maintaining dialysate magnesium at 1.0 mEq/L on T
50
in subjects undergoing hemodialysis for ESKD. The primary end point was the value of T
50
at the end of the intervention.
Results
Fifty-nine subjects were enrolled in the trial, and of these, 57 completed the intervention and were analyzed for the primary outcome. In the standard dialysate magnesium group, T
50
was 233±81 minutes (mean±SD) at baseline (mean of days −7 and 0) and 229±93 minutes at follow-up (mean of days 21 and 28), whereas in the high dialysate magnesium group, T
50
was 247±69 minutes at baseline and 302±66 minutes at follow-up. The difference in T
50
between the two groups at follow-up (primary analysis) was 73 minutes (between-group difference; 95% confidence interval, 30 to 116;
P
<0.001), and the between-group difference in serum magnesium was 0.88 mg/dl (95% confidence interval, 0.66 to 1.10;
P
=0.001).
Conclusions
Increasing dialysate magnesium increases T
50
and hence, decreases calcification propensity in subjects undergoing maintenance hemodialysis.
Podcast
This article contains a podcast at
https://www.asn-online.org/media/podcast/CJASN/2018_08_21_CJASNPodcast_18_9_B.mp3
Open multimedia modal
Copyright © 2018 by the American Society of Nephrology
Advertisement
Article Level Metrics

Advertisement
Related Articles
Advertisement
Readers Of this Article Also Read
Advertisement
Most Popular Articles
Advertisement
Advertisement
Customer Service
Submit a Service Request
Browse the help center
Follow Us
Privacy policy
Open Access Policy
Legal disclaimer
Terms and Copyright
Manage Cookie Preferences
Your California Privacy Choices
Copyright © 2026 Wolters Kluwer N.V. and/or its subsidiaries or third-party licensors. All rights reserved, including those for text and data mining and artificial intelligence training. For all open access content, the relevant licensing terms apply.
</reference>

<statements>
1. In a single-center randomized controlled trial in hemodialysis patients, increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days raised serum magnesium by 0.88 mg/dL (95% CI 0.66–1.10) and increased T50, a measure of serum calcification propensity, by 73 minutes (95% CI 30–116; P < 0.001) compared with standard dialysate magnesium
2. Lower T50 represents higher calcification propensity and is associated with greater cardiovascular risk and death in end-stage kidney disease, but the trial did not measure cardiovascular events
3. Dialysate magnesium can raise serum magnesium and improve a calcification-propensity biomarker in hemodialysis, but it remains surrogate
</statements>

Begin the assessment now. Output only the JSON list, without any conversational text or explanations.